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Abstract
Background: The objective of this study was to analyze the extracellularly acting semicarbazide-
sensitive amine oxidase (SSAO) serum levels in children with ADHD for the first time. SSAO is
known to show deviations from normal in various somatic disorders and to interplay with the
intracellularly active MAO. In humans two forms of SSAO a circulating form in plasma and a
membrane-bound form are involved in monoaminergic metabolism.
Methods:  We analyzed serum levels of SSAO in 27 children meeting ICD-10 criteria of
Hyperkinetic Disorder (F90) or DSM-IV criteria of ADHD combined type by HPLC method and
fluorimetric detection. A group of 42 healthy volunteers within the same age range (7.0 – 14.0
years) served as controls.
Results: No significant differences between children with ADHD (SSAO activity M = 773, SD =
217 mU/l) and healthy controls (SSAO activity M = 775, SD = 256 mU/l) in SSAO serum levels were
found (F = 2.18; p > 0.14). Further, stimulant medication status had no influence on the result (F =
2.52; p > 0.11).
Conclusion: There is no evidence for a deviation of SSAO serum activity in ADHD. Hence,
extracellularly acting SSAO does not seem to be a promising factor for further research in ADHD.
But progress in knowledge of its physiologic role and of the relationship between the membrane-
bound and the circulating serum form may open new avenues for research on SSAO in ADHD.
Background
There is increasing evidence that deviations of the
dopaminergic, noradrenergic, and serotonergic systems
are involved in attention deficit hyperactivity disorder
(ADHD) [1]. Several biogenic amines of these systems are
degraded by oxidative deamination via the intracellular
enzyme group monoamine oxidases (MAO). Thus the lat-
ter play an important role concerning the modification of
signal transduction within these neurotransmitter systems
[2].
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In children with ADHD, significantly lower levels of plate-
let MAO activity seem to be associated with increased
impulsivity and inattention [3]. In addition, different
medications with MAO inhibiting properties have been
shown to be effective in the pharmacological treatment of
ADHD (for a review see [4,5]). Further, MAO seems to be
a good candidate for genetic investigations of ADHD since
DNA variations in this gene may play a role in the predis-
position to the disorder. However, studies showed mixed
results [6-9] and focusing on the intracellularly acting
MAO only seems to be a too narrow look.
Other aminoxidases like the semicarbacide sensitive
amino oxidase (SSAO) may also be involved in ADHD.
Since SSAO acts extracellularly, it may work complemen-
tary to the intracellular activity of MAO [10]. Additionally,
there is direct physiological interplay between the activi-
ties of SSAO and MAO [11].
In humans two forms of SSAO have been detected: a cir-
culating form in plasma and a membrane-bound form.
Both forms of SSAO metabolize several aromatic and
aliphatic primary amines including dopamine while gen-
erating at the same time hydrogen peroxide and ammo-
nia. The presence of SSAO in human cerebrovascular
tissues and in endothelial cells from microvessels (includ-
ing the blood-brain barrier) [12,13] (for a review see[14])
supports its impact on CNS metabolism and makes it a
candidate to be investigated in ADHD.
Therefore, to shed more light on this issue our pilot-study
analyzed the extracellularly acting SSAO serum levels in
ADHD for the first time.
Methods and materials
Patients
A total of 27 children meeting ICD-10 criteria of Hyperk-
inetic Disorder (F90) or DSM-IV criteria of ADHD com-
bined type (assessment by clinical interview, physical
examination and Diagnostic Checklist, DCL-HKS [15])
(age range 7.0 – 14.0 years) were included. All were
recruited sequentially from the outpatient clinic of the
Department of Child and Adolescent Psychiatry of the
University of Erlangen-Nuremberg (n = 12) and the Uni-
versity of Goettingen (n = 15). Further inclusion criteria
were the following: intelligence IQ ≥ 85, body weight > 20
kg. Exclusion criteria were a clinical diagnosis of a devel-
opmental disorder or psychosis, depressive disorder, anx-
iety disorder, tic disorder, substance abuse, previous or
recent epilepsy, EEG registration indicating epileptiform
activity, previous/recent internal medicine or other neuro-
logical problems or treatment with known SSAO-inhibi-
tory substances (i.e. tricyclic antidepressants) or other
antidepressants. 13 children received methylphenidate,
14 were medication free.
A group of 42 healthy volunteers within the same age
range (7.0 – 14.0 years) served as controls.
In view of the fact that SSAO circulating in plasma is quite
stable [16] only one blood sample was collected from
each participant. Because in SSAO activity no sex differ-
ences and no effect of body position (standing, sitting,
supine) as well as of time of day of blood sampling has
been observed[17,18], we did not control for these condi-
tions.
This pilot study was carried out with the approval of the
local Ethics Committees of the Medical Faculties of the
Universities of Erlangen-Nuremberg and Goettingen.
Written informed consent has been obtained from all par-
ents and the patients able to write; younger children gave
their oral assent.
Laboratory methods
The SSAO activity was determined according to a method
of van Dijk et al. [19], modified in a few points. Initially,
the enzymes MAO-A and MAO-B were inhibited in a 30-
minute pre-incubation with chlorgyline, followed by con-
version of benzylamine to benzaldehyde catalyzed by
SSAO at 37°C over 60 minutes.
After precipitation of the proteins contained in the reac-
tion mixture and stopping of the reaction, the benzalde-
hyde formed was derivatized with 5,5-dimethyl-1,3-
cyclohexandione (dimedone) from the supernatant,
which specifically reacts with aldehydes. The derived
material was quantified using an isocratic HPLC method
and fluorimetric detection (λ excitation 386 nm, λ emis-
sion 451 nm). For evaluation of the chromatograms, the
software ChromGate, Version 2.8 (Knauer) was used.
In the present study, in contrast to the method of van Dijk
et al. [19], serum was used as sample material instead of
plasma. In addition, semicarbazide was used as an inhib-
itor for the sample blanks, since the MDL-72,145A used
by van Dijk et al. [19] does not have any particular advan-
tages over semicarbazide and the inhibition of the SSAO
with semicarbazide is better established in the literature.
Semicarbazide does not interfere either with the chroma-
togram or with the derivatization reaction of benzalde-
hyde.
In several tests, it was established that, by acidification
with hydrochloric acid instead of sulfuric acid, and a pH
range thus set at between 4.0 and 5.1, the derivatization
was completed within 45 min and thus produced maxi-
mal measurement signals.
The problem described by van Dijk et al. [19] that the
excess pressure developed in the reaction vessels by theBehavioral and Brain Functions 2006, 2:5 http://www.behavioralandbrainfunctions.com/content/2/1/5
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temperature increase caused the lids to blow off if a hole
was not made in the lids, was avoided here by using
threaded vessels with a rubber seal (Sarstedt).
Statistics
Statistical analysis was performed using univariate analy-
sis of variance to test the effect of group and medication
status. The analyses were carried out using SPSS statistical
software (SPSS, release 10.0.5 for Windows).
Results
In controls and ADHD children the SSAO serum activity
(Fig. 1) was within the range of the sample of Boomsma
et al. [16] with 147 healthy children and adolescents
(about 620 ± 250 mU/l). The somewhat lower SSAO
activity in the latter study, compared to the values pre-
sented here, might be due to age effects with older chil-
dren in Boomsma et al. [16].
The univariate analysis of variance revealed no differences
between children with ADHD (SSAO activity M = 773, SD
= 217 mU/l) and healthy children (SSAO activity M = 775,
SD = 256 mU/l) (F = 0.86; p > 0.36; ηp
2 = 0.01; df = 1) and
no influence of stimulant medication status (F = 2.52; p >
0.12; ηp
2 = 0.04; df = 1).
Discussion
The present study investigated the first time extracellularly
acting SSAO in children with ADHD to test for its possible
role within the neurobiological background of this disor-
der. No significant differences between children with
ADHD and healthy controls in SSAO serum levels were
found. Further, stimulant medication status had no influ-
ence on the result.
The finding is in line with normal SSAO levels in sponta-
neously hypertensive rats (SHR; an animal model of
ADHD) [20-22] and questions a differentiating influence
of SSAO in ADHD.
Reduced quality of measurement underlying the lack of
differences could be excluded due to our findings of stable
SSAO serum activity in healthy adults (two blood samples
per person, three hours apart) [23]. But several limitations
might contribute to the absence of found group differ-
ences.
In human brain the existence of SSAO is still under con-
sideration [14]. Due to its selective, membrane-bound
expression in human brain blood vessels, but not in brain
parenchyma (i.e. neurons and glial cells) [12,13] SSAO
has been related to the blood-brain barrier in addition to
the better known, intracellularly acting MAO [24]. Both
metabolize circulating amines to maintain brain homeos-
tasis. The origin of the circulating serum SSAO (analyzed
in the present study) and its relationship to the mem-
brane-bound form is still a matter of debate [16]. It seems
to be released mainly from vascular endothelial cells
[25,26], adipocytes [27] and to some part from skeleton
[28]. However at present it is only justifiable to examine
serum SSAO, because the examination of the membrane-
bound form in humans is restricted to highly invasive
techniques of tissue extraction. Thus, the present analysis
of SSAO serum activity reflects only one portion of the
SSAO system possibly involved in monoaminergic abnor-
malities in ADHD.
The small effect sizes of aminoxidase differences found in
mental disorders, e.g. MAO in schizophrenia [29], might
also be present in SSAO and thus contribute to the
absence of SSAO differences in our small sample. How-
ever, alterations in SSAO activity observed in disease states
are generally more dramatic than those reported for MAO
[10]. But we detected only small effects according to
Cohen [30] concerning the absence of both group differ-
ences of SSAO serum activity and of influence of medica-
tion status. Nevertheless, there exists some, albeit
equivocal, evidence for an ADHD specific alteration con-
cerning catechol-O-methyltransferase (COMT) gene and
MAO A and B genes as well as MAO serum levels (e.g.
SSAO serum activity (mU/l) in children with ADHD and con- trols Figure 1
SSAO serum activity (mU/l) in children with ADHD and con-
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lower levels of platelet MAO activity in untreated children
and adolescents with ADHD [3]).
Thus our negative finding concerning group differences of
SSAO serum activity has to be interpreted with some cau-
tion because it is difficult to be certain to what extent it
may reflect a lack of statistical power to detect small effect
sizes.
Conclusion
In sum, there is no evidence for a deviation of SSAO
serum activity in ADHD. Hence, extracellularly acting
SSAO does not seem to be a promising factor for further
research in ADHD. But progress in knowledge of its phys-
iologic role and of the relationship between the mem-
brane-bound and the circulating serum form may open
new avenues for research on SSAO in ADHD.
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